Picture of HUTCHMED (China) logo

HCM HUTCHMED (China) Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+27.31%
3m-9.45%
6m+10.02%
1yr+7.67%
Volume Change (%)
10d/3m+32.33%
Price vs... (%)
52w High-16.27%
50d MA+21.91%
200d MA+14.84%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value4.28
Price to Tang. Book4.28
Price to Free Cashflow16.77
Price to Sales3.74
EV to EBITDA112.55

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital1.44%
Return on Equity15.03%
Operating Margin1.5%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of HUTCHMED (China) EPS forecast chart

Profile Summary

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
December 18th, 2000
Public Since
May 19th, 2006
No. of Employees
1,988
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
871,256,270
Blurred out image of a map
Address
48Th Floor, Cheung Kong Center
Web
https://www.hutch-med.com/
Phone
+852 21281188
Contact
David Ng
Auditors
PricewaterhouseCoopers

HCM Share Price Performance

Upcoming Events for HCM

HUTCHMED (China) Ltd Annual Shareholders Meeting

Half Year 2024 HUTCHMED (China) Ltd Earnings Release

Similar to HCM

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of AstraZeneca logo

AstraZeneca

gb flag iconLondon Stock Exchange

Picture of Beximco Pharmaceuticals logo

Beximco Pharmaceuticals

gb flag iconLondon Stock Exchange

Picture of BSF Enterprise logo

BSF Enterprise

gb flag iconLondon Stock Exchange

FAQ